0

Category: CMHC

Cardiometabolic Health Congress

First “Follow-On” Insulin Now Available in the United States

One year after the US FDA granted approval to the first “follow-on” insulin, the long-acting insulin glargine product has been officially launched in the United States. Approved as a follow-on and not a biosimilar, the long-acting insulin glargine has already been made available in Europe, and is available as a 100 Units/mL strength in 3-mL prefilled pens. It can be used in both children and adults with type 1 diabetes and adults with type 2 diabetes.

References:

Basaglar now available for type 1, type 2 diabetes.

FDA approves Basaglar, the first “follow-on” insulin glargine product to treat diabetes.

Eugene Braunwald, MD joins roster of expert faculty for the 12th Annual CMHC

Just Announced –

Eugene Braunwald, MD joins roster of expert faculty for the 12th Annual CMHC – October 4-7, 2017, Boston, MA

Dr. Braunwald, Professor at Harvard Medical School, is a world-renowned expert in the field of cardiovascular medicine and is believed to be the most frequently cited author in the field of cardiology, with more than 1000 publications in peer-reviewed journals. His landmark research includes the identification of hypertrophic cardiomyopathy as a clinical entity. As Founder and Chairman of the TIMI Study Group, one of their many achievements was the PROVE-IT TIMI 22 Trial, which demonstrated the benefit of intensive reduction of LDL cholesterol by statin therapy. Dr. Braunwald will be joining a panel at the 12th Annual CMHC that includes Drs. Christie Ballantyne, Paul Ridker, and Marc Sabatine to discuss the clinical trials FOURIER, REVEAL, and CANTOS.